-
5-HTP and Creatine for Depression R33 Phase
NCT05895747 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
NCT05507138 ·
Phase: Phase 2 ·
Ages: 50 Years to 79 Years ·
Sex: All (male and female) · 1 location
-
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
NCT06597695 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female) · 1 location
-
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
NCT06820723 ·
Phase: Phase 2 ·
Ages: 21 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A New Intervention to Improve Function in Veterans With Anxiety and Depression
NCT06188923 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT07115329 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female) · 32 locations
-
A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
NCT06236880 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Randomized Neuroimaging Trial of Psilocybin in Depression
NCT06072898 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female) · 1 location
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
NCT06696755 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 33 locations
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
NCT07276997 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 33 locations
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 48 locations
-
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 25 locations
-
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
NCT07610473 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 23 locations
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 43 locations
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 61 locations
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
NCT07193901 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female) · 8 locations
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 26 locations
-
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 27 locations
-
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 48 locations
-
Accelerated rTMS vs. Sham for Stroke Apathy
NCT07113067 ·
Phase: Phase 1, Phase 2 ·
Ages: 40 Years and older ·
Sex: All (male and female) · 1 location
-
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
NCT06706232 ·
Phase: Phase 2 ·
Ages: 25 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
NCT05685368 ·
Phase: Phase 1, Phase 2 ·
Ages: 14 Years to 21 Years ·
Sex: All (male and female) · 1 location
-
Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian
NCT07399626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female) · 1 location
-
Adolescent Chatbot
NCT07094503 ·
Phase: Phase 2 ·
Ages: 13 Years to 19 Years ·
Sex: All (male and female) · 2 locations
-
Allopregnanolone (Zuranolone) in Post-stroke Depression
NCT06759558 ·
Phase: Phase 2 ·
Ages: 21 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Allopurinol in Depression
NCT07574060 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
NCT05660642 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 3 locations
-
Apimostinel + Automated Neurocognitive Training for Depression
NCT06400121 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
NCT05457465 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
NCT05869682 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: Male · 1 location
-
COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients
NCT07012772 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Cancer Related Major Depression Treated With a Single Dose of Psilocybin
NCT06319378 ·
Phase: Phase 2 ·
Ages: 20 Years to 80 Years ·
Sex: All (male and female) · 4 locations
-
Cannabidiol Oil for Treatment-Resistant Major Depression
NCT07696871 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 69 Years ·
Sex: All (male and female) · 1 location
-
Cannabidiol and Older Adult Cannabis Users
NCT06290063 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
Cannabidiol for Reduction of Brain Neuroinflammation
NCT05066308 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
Cannabis for Palliative Care in Cancer
NCT06266611 ·
Phase: Phase 2 ·
Ages: 25 Years and older ·
Sex: All (male and female) · 1 location
-
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
NCT06591091 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 31 locations
-
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
NCT06967857 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
NCT06136546 ·
Phase: Phase 2 ·
Ages: 25 Years to 50 Years ·
Sex: All (male and female) · 1 location
-
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
NCT05474846 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
NCT06375083 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
NCT06751784 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Dapagliflozin in Depression
NCT07239011 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
NCT07523048 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Dog Presence and Oxytocin on Trust Towards Therapists
NCT06248710 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
NCT06828887 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
NCT07226661 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Effect of Probiotics "Psychobiotics" on Depression and Metabolic Syndrome in Saudi Arabia
NCT06765057 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
NCT06088732 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
NCT06667180 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder
NCT05837104 ·
Phase: Phase 2 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female) · 2 locations
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
NCT06273527 ·
Phase: Phase 2, Phase 3 ·
Ages: 21 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Enoxolone in Major Depression - Biomarker-outcome Relationship
NCT05570110 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Evaluating the Effectiveness of the Common Elements Treatment Approach (CETA) in Peru: Mechanisms of Individual and Intergenerational Change
NCT07667738 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female · 1 location
-
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
NCT07211438 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 2 locations
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
NCT06263660 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Family Acceptance Project Online (Pilot RCT)
NCT06839859 ·
Phase: Phase 2 ·
Ages: 14 Years and older ·
Sex: All (male and female) · 1 location
-
Feasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study
NCT07051980 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)
NCT06557525 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
NCT06799351 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
NCT06901687 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Imaging Depression in Parkinson's Disease
NCT06402955 ·
Phase: Phase 2 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
NCT06512220 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Inflammation and Depression in People With HIV
NCT05849038 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
Inhaled DMT for Major Depressive Disorder
NCT07562191 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 5 locations
-
Intravenous Ketamine for Treatment-Resistant Depression
NCT06668571 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
NCT06511908 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Investigation to Understand and Optimize Psilocybin
NCT06512194 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
JAK Signaling in Depression
NCT07003997 ·
Phase: Phase 2 ·
Ages: 25 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Ketamine Alcohol (in Treatment-Resistant Depression)
NCT02122562 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
NCT07569198 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Ketamine for Combined Depression and Alcohol Use Disorder
NCT06090422 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Ketamine for Veterans With Parkinson's Disease
NCT06231563 ·
Phase: Phase 2 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
NCT06559826 ·
Phase: Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression
NCT06419439 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Leucine in Midlife Depression
NCT06580145 ·
Phase: Phase 2 ·
Ages: 35 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City
NCT07673380 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
NCT06529029 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Lysergic Acid Diethylamide (LSD) in Palliative Care
NCT05883540 ·
Phase: Phase 2 ·
Ages: 22 Years and older ·
Sex: All (male and female) · 8 locations
-
Maternal Mental Health Trial
NCT04685148 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 45 Years ·
Sex: Female · 1 location
-
Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial
NCT06626152 ·
Phase: Phase 2 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
Metreleptin in Anorexia Nervosa
NCT06305182 ·
Phase: Phase 2 ·
Ages: 17 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Mindfulness Engaged Neurostimulation for Depression (MEND II)
NCT07512284 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Mindfulness-based Psilocybin Therapy for PTSD
NCT07104916 ·
Phase: Phase 2 ·
Ages: 21 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Modulating Exercise Dosage to Improve Concussion Recovery
NCT05434130 ·
Phase: Phase 1, Phase 2 ·
Ages: 13 Years to 18 Years ·
Sex: All (male and female) · 3 locations
-
Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
NCT06795451 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 26 locations
-
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
NCT05136755 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
NMDA Modulation in Major Depressive Disorder
NCT04637620 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
NCT05977023 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
NCT04751331 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
NCT05570812 ·
Phase: Phase 2 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
Neurobiology of Suicide
NCT02543983 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Neutralizing Interleukin (IL)-6
NCT07493317 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Nitrous Oxide in the Treatment of Acute Suicidal Ideation
NCT06636357 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
OSU6162 as add-on in SSRI/SNRI-resistant Depression
NCT05641623 ·
Phase: Phase 2 ·
Ages: 25 Years to 75 Years ·
Sex: All (male and female) · 4 locations
-
OSU6162 in Bipolar Depression (OBID)
NCT05296356 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
NCT06854224 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
NCT06706544 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
Showing 100 of 147 recruiting trials.